These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups. Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706 [TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464 [TBL] [Abstract][Full Text] [Related]
24. Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Liu L; Ruiz J; O'Neill SS; Grant SC; Petty WJ; Yang M; Chen K; Topaloglu U; Pasche B; Zhang W Mol Cancer; 2018 Apr; 17(1):81. PubMed ID: 29650000 [TBL] [Abstract][Full Text] [Related]
25. Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma. Raffone A; Travaglino A; Raimondo D; Boccellino MP; Maletta M; Borghese G; Casadio P; Insabato L; Mollo A; Zullo F; Seracchioli R Gynecol Oncol; 2021 May; 161(2):621-628. PubMed ID: 33715893 [TBL] [Abstract][Full Text] [Related]
27. Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer. Fang H; Barbour JA; Poulos RC; Katainen R; Aaltonen LA; Wong JWH PLoS Genet; 2020 Feb; 16(2):e1008572. PubMed ID: 32012149 [TBL] [Abstract][Full Text] [Related]
28. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns. Hu H; Cai W; Wu D; Hu W; Dong Wang L; Mao J; Zheng S; Ge W Cancer Med; 2021 Jan; 10(1):135-142. PubMed ID: 33125191 [TBL] [Abstract][Full Text] [Related]
29. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations. Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482 [TBL] [Abstract][Full Text] [Related]
30. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis. Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355 [TBL] [Abstract][Full Text] [Related]
31. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis. Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754 [TBL] [Abstract][Full Text] [Related]
32. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability. Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608 [TBL] [Abstract][Full Text] [Related]
33. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Church DN; Briggs SE; Palles C; Domingo E; Kearsey SJ; Grimes JM; Gorman M; Martin L; Howarth KM; Hodgson SV; ; Kaur K; Taylor J; Tomlinson IP Hum Mol Genet; 2013 Jul; 22(14):2820-8. PubMed ID: 23528559 [TBL] [Abstract][Full Text] [Related]
35. Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity. Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550 [TBL] [Abstract][Full Text] [Related]
36. Clinical and Molecular Characterization of Garmezy B; Gheeya J; Lin HY; Huang Y; Kim T; Jiang X; Thein KZ; Pilié PG; Zeineddine F; Wang W; Shaw KR; Rodon J; Shen JP; Yuan Y; Meric-Bernstam F; Chen K; Yap TA JCO Precis Oncol; 2022 Feb; 6():e2100267. PubMed ID: 35108036 [TBL] [Abstract][Full Text] [Related]
37. Expression of the cancer-associated DNA polymerase ε P286R in fission yeast leads to translesion synthesis polymerase dependent hypermutation and defective DNA replication. Soriano I; Vazquez E; De Leon N; Bertrand S; Heitzer E; Toumazou S; Bo Z; Palles C; Pai CC; Humphrey TC; Tomlinson I; Cotterill S; Kearsey SE PLoS Genet; 2021 Jul; 17(7):e1009526. PubMed ID: 34228709 [TBL] [Abstract][Full Text] [Related]
38. Functional Analysis of Cancer-Associated DNA Polymerase ε Variants in Barbari SR; Kane DP; Moore EA; Shcherbakova PV G3 (Bethesda); 2018 Mar; 8(3):1019-1029. PubMed ID: 29352080 [TBL] [Abstract][Full Text] [Related]
40. High polymerase ε expression associated with increased CD8+T cells improves survival in patients with non-small cell lung cancer. Min KW; Kim WS; Kim DH; Son BK; Oh YH; Kwon MJ; Lee HS; Lee SE; Kim IA; Moon JY; Kim KY; Park JH PLoS One; 2020; 15(5):e0233066. PubMed ID: 32433714 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]